MA29098B1 - Compositions pour le traitement du vhc - Google Patents

Compositions pour le traitement du vhc

Info

Publication number
MA29098B1
MA29098B1 MA30000A MA30000A MA29098B1 MA 29098 B1 MA29098 B1 MA 29098B1 MA 30000 A MA30000 A MA 30000A MA 30000 A MA30000 A MA 30000A MA 29098 B1 MA29098 B1 MA 29098B1
Authority
MA
Morocco
Prior art keywords
hcv
compositions
treatment
Prior art date
Application number
MA30000A
Other languages
English (en)
Inventor
Kai Lin
Beat Weidmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29098B1 publication Critical patent/MA29098B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MA30000A 2004-12-23 2007-06-18 Compositions pour le traitement du vhc MA29098B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63867504P 2004-12-23 2004-12-23

Publications (1)

Publication Number Publication Date
MA29098B1 true MA29098B1 (fr) 2007-12-03

Family

ID=36155247

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30000A MA29098B1 (fr) 2004-12-23 2007-06-18 Compositions pour le traitement du vhc

Country Status (16)

Country Link
US (1) US7897565B2 (fr)
EP (1) EP1830871A1 (fr)
JP (1) JP2008525459A (fr)
KR (1) KR20070087624A (fr)
CN (1) CN101076350A (fr)
AU (1) AU2005322242B2 (fr)
BR (1) BRPI0519345A2 (fr)
CA (1) CA2587793A1 (fr)
IL (1) IL183659A0 (fr)
MA (1) MA29098B1 (fr)
MX (1) MX2007007779A (fr)
NO (1) NO20073764L (fr)
NZ (1) NZ555143A (fr)
RU (1) RU2007128099A (fr)
WO (1) WO2006071619A1 (fr)
ZA (1) ZA200703908B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
BRPI0513370A (pt) 2004-07-14 2008-05-06 Novartis Ag uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
WO2006071618A1 (fr) * 2004-12-23 2006-07-06 Novartis Ag Composes pour le traitement des infections virales par flaviviridae
CA2587793A1 (fr) 2004-12-23 2006-07-06 Novartis Ag Compositions pour le traitement du vhc
AR054778A1 (es) * 2005-06-17 2007-07-18 Novartis Ag Uso de sangliferina en hcv
EP1909564A4 (fr) * 2005-07-18 2010-06-30 Novartis Ag Modele petit animal pour une replication hcv
US8329658B2 (en) 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
BRPI0616476A2 (pt) 2005-09-30 2011-06-21 Scynexis Inc uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica
JP2007112775A (ja) * 2005-10-24 2007-05-10 Hamamatsu Univ School Of Medicine サイトメガロウイルス感染の処置におけるシクロスポリン類の使用
ATE502633T1 (de) 2006-05-19 2011-04-15 Scynexis Inc Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
BRPI0719189A2 (pt) * 2006-10-12 2018-08-14 Univ Kyushu Nat Univ Corp uso de ciclosporinas modificadas
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
EP2376524B1 (fr) 2008-12-31 2017-03-15 Cypralis Limited Dérivés de cyclosporine a
US10752611B2 (en) 2009-02-27 2020-08-25 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
BR112012014729A2 (pt) * 2009-12-18 2016-03-29 Boehringer Ingelheim Int terapia combinada contra hcv
KR20140035305A (ko) 2010-10-05 2014-03-21 노파르티스 아게 C형 간염 바이러스 감염의 새로운 치료법
BR112013013166A2 (pt) 2010-11-30 2016-09-06 Novartis Ag tratamentos da infecção pelo vírus da hepatite c
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
CN105749246A (zh) 2011-03-31 2016-07-13 诺华股份有限公司 治疗丙肝病毒感染的阿拉泊韦
PL2694087T3 (pl) 2011-04-01 2015-06-30 Novartis Ag Leczenie zakażenia wirusem zapalenia wątroby typu B samego lub w połączeniu z zakażeniem wirusem zapalenia wątroby typu delta i towarzyszącymi chorobami wątroby
SG10201602184TA (en) 2011-04-13 2016-04-28 Novartis Ag Treatment of hepatitis c virus infection with alisporivir
KR20140070565A (ko) 2011-09-27 2014-06-10 노파르티스 아게 C형 간염 바이러스 감염의 치료를 위한 알리스포리비르
SG11201406441RA (en) 2012-05-07 2014-11-27 Novartis Ag Pharmacokinetic modulation with alisporivir
WO2015008223A1 (fr) 2013-07-17 2015-01-22 Novartis Ag Traitement du virus de l'hépatite c avec l'alisporivir et la ribavirine
TW201536789A (zh) 2013-07-29 2015-10-01 Enanta Pharm Inc Ｃ型肝炎病毒抑制劑
WO2015136455A1 (fr) 2014-03-13 2015-09-17 Novartis Ag Nouveaux traitements d'une infection par le virus de l'hépatite c
EP4483875A3 (fr) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
EP3455219A4 (fr) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. Dégronimères de c3-glutarimide liés à une amine pour la dégradation de protéines cibles
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP3641762B1 (fr) 2017-06-20 2026-02-18 C4 Therapeutics, Inc. Dégrons et dégronimères à liaison n/o pour la dégradation de protéines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
ATE148469T1 (de) 1990-11-02 1997-02-15 Sandoz Ag Zyklosporine
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US20030216303A1 (en) 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
AR031010A1 (es) * 2000-10-19 2003-09-03 Fujisawa Pharmaceutical Co Una composicion farmaceutica, util para inhibir el dano celular
AR036081A1 (es) * 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
US20030213603A1 (en) * 2002-05-14 2003-11-20 Fisher David B. Dual use extension apparatus for a tool
CN1678326A (zh) * 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
CA2503693A1 (fr) * 2002-10-29 2004-05-13 Coley Pharmaceutical Group, Ltd. Techniques et produits relatifs au traitement et a la prevention de l'infection par le virus de l'hepatite c
RU2005123395A (ru) * 2002-12-23 2006-01-27 Айденикс (Кайман) Лимитед (Ky) Способ получения 3-нуклеозидных пролекарств
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
UA88484C2 (ru) 2004-10-01 2009-10-26 Дебиофарм Са ПРИМЕНЕНИЕ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИНА ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИИ ГЕПАТИТА С И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ВКЛЮЧАЕТ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИН
CA2587793A1 (fr) 2004-12-23 2006-07-06 Novartis Ag Compositions pour le traitement du vhc

Also Published As

Publication number Publication date
KR20070087624A (ko) 2007-08-28
IL183659A0 (en) 2007-09-20
CA2587793A1 (fr) 2006-07-06
US7897565B2 (en) 2011-03-01
BRPI0519345A2 (pt) 2009-01-20
MX2007007779A (es) 2007-08-14
JP2008525459A (ja) 2008-07-17
WO2006071619A1 (fr) 2006-07-06
AU2005322242A1 (en) 2006-07-06
ZA200703908B (en) 2009-06-24
AU2005322242B2 (en) 2010-02-11
EP1830871A1 (fr) 2007-09-12
NZ555143A (en) 2009-12-24
NO20073764L (no) 2007-09-18
RU2007128099A (ru) 2009-01-27
US20090104149A1 (en) 2009-04-23
CN101076350A (zh) 2007-11-21

Similar Documents

Publication Publication Date Title
EP1931691A4 (fr) Inhibiteurs d'odcase pour le traitement du paludisme
EP1898930A4 (fr) Traitement d'etats inflammatoires
DE602005015234D1 (de) Zusammensetzungen zur wäschebehandlung
DE602005014252D1 (de) Zusammensetzungen zur wäschebehandlung
EP1765288A4 (fr) Methodes de traitement d'infections endobronchiques
FR13C0030I1 (fr) Compositions pour le traitement de troubles gastrointestinaux
EP1804761A4 (fr) Compositions et methodes pour traitement des dyschromies cutanees
EP1940437A4 (fr) Compositions et procedes pour le traitement de bacteries
EP1968582A4 (fr) Traitement du lymphome t cutane
FR2871696B1 (fr) Composition topique pour le traitement du psoriasis
EP1725535A4 (fr) Inhibiteurs de l'integrase du vih
IL176584A0 (en) Photoresist compositions and processes of use
MA29097B1 (fr) Composes pour le traitement des infections virales par flaviviridae
EP1720856A4 (fr) Inhibiteurs de l'integrase du vih
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ZA200703908B (en) Compositions for HCV treatment
MA28519B1 (fr) Inhibiteurs de l'integrase du vih
DK1592384T3 (da) Cop 1 til behandling af inflammatoriske tarmsygdomme
ZA200800448B (en) Methods and compositions for the prevention and treatment of inflammatory disease
EP1725102A4 (fr) Inhibiteurs de l'integrase du vih
EP1804787A4 (fr) Composition flavonoide pour le traitement des maladies bucco-dentaires
EP1881825A4 (fr) Inhibiteurs de l'intégrase du vih
EP1789069A4 (fr) Peptides cycliques pour le traitement de cachexie
EP1756114A4 (fr) Inhibiteurs de l'integrase du vih
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine